扶桑薬品工業の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2025/02/04 | 2,417 | 2,420 | 2,395 | 2,399 | -1 | ±0% | 23,100 |
| 2025/02/03 | 2,429 | 2,429 | 2,388 | 2,400 | -35 | -1.4% | 17,900 |
| 2025/01/31 | 2,488 | 2,488 | 2,431 | 2,435 | -44 | -1.8% | 3,800 |
| 2025/01/30 | 2,463 | 2,486 | 2,446 | 2,479 | +9 | +0.4% | 12,900 |
| 2025/01/29 | 2,461 | 2,494 | 2,461 | 2,470 | +7 | +0.3% | 14,200 |
| 2025/01/28 | 2,437 | 2,475 | 2,437 | 2,463 | +11 | +0.4% | 5,900 |
| 2025/01/27 | 2,433 | 2,475 | 2,400 | 2,452 | +33 | +1.4% | 15,000 |
| 2025/01/24 | 2,380 | 2,419 | 2,380 | 2,419 | +52 | +2.2% | 18,100 |
| 2025/01/23 | 2,433 | 2,433 | 2,361 | 2,367 | -62 | -2.6% | 35,300 |
| 2025/01/22 | 2,446 | 2,450 | 2,425 | 2,429 | -17 | -0.7% | 7,900 |
| 2025/01/21 | 2,481 | 2,481 | 2,434 | 2,446 | -19 | -0.8% | 12,100 |
| 2025/01/20 | 2,449 | 2,471 | 2,442 | 2,465 | +19 | +0.8% | 13,500 |
| 2025/01/17 | 2,465 | 2,480 | 2,437 | 2,446 | -6 | -0.2% | 10,300 |
| 2025/01/16 | 2,494 | 2,518 | 2,451 | 2,452 | -38 | -1.5% | 11,300 |
| 2025/01/15 | 2,438 | 2,493 | 2,438 | 2,490 | +52 | +2.1% | 14,400 |
| 2025/01/14 | 2,432 | 2,449 | 2,418 | 2,438 | -2 | -0.1% | 14,900 |
| 2025/01/10 | 2,469 | 2,469 | 2,431 | 2,440 | -19 | -0.8% | 9,500 |
| 2025/01/09 | 2,460 | 2,474 | 2,442 | 2,459 | +3 | +0.1% | 19,200 |
| 2025/01/08 | 2,510 | 2,510 | 2,451 | 2,456 | -64 | -2.5% | 28,900 |
| 2025/01/07 | 2,566 | 2,587 | 2,513 | 2,520 | -17 | -0.7% | 20,800 |
| 2025/01/06 | 2,592 | 2,592 | 2,534 | 2,537 | -5 | -0.2% | 17,900 |
| 2024/12/30 | 2,533 | 2,550 | 2,493 | 2,542 | +14 | +0.6% | 11,400 |
| 2024/12/27 | 2,538 | 2,558 | 2,500 | 2,528 | -7 | -0.3% | 22,400 |
| 2024/12/26 | 2,502 | 2,535 | 2,501 | 2,535 | +26 | +1% | 18,600 |
| 2024/12/25 | 2,525 | 2,535 | 2,440 | 2,509 | -25 | -1% | 20,600 |
| 2024/12/24 | 2,559 | 2,570 | 2,521 | 2,534 | -7 | -0.3% | 5,900 |
| 2024/12/23 | 2,571 | 2,581 | 2,541 | 2,541 | -26 | -1% | 5,500 |
| 2024/12/20 | 2,616 | 2,621 | 2,567 | 2,567 | -23 | -0.9% | 26,000 |
| 2024/12/19 | 2,553 | 2,612 | 2,553 | 2,590 | +14 | +0.5% | 9,000 |
| 2024/12/18 | 2,562 | 2,613 | 2,562 | 2,576 | +6 | +0.2% | 11,300 |
| 2024/12/17 | 2,615 | 2,620 | 2,556 | 2,570 | -37 | -1.4% | 14,500 |
| 2024/12/16 | 2,560 | 2,615 | 2,540 | 2,607 | +78 | +3.1% | 25,600 |
| 2024/12/13 | 2,478 | 2,537 | 2,478 | 2,529 | +13 | +0.5% | 17,000 |
| 2024/12/12 | 2,507 | 2,522 | 2,500 | 2,516 | +27 | +1.1% | 11,700 |
| 2024/12/11 | 2,500 | 2,500 | 2,462 | 2,489 | +7 | +0.3% | 17,000 |
| 2024/12/10 | 2,528 | 2,528 | 2,481 | 2,482 | -19 | -0.8% | 8,900 |
| 2024/12/09 | 2,498 | 2,525 | 2,491 | 2,501 | +11 | +0.4% | 10,000 |
| 2024/12/06 | 2,549 | 2,549 | 2,486 | 2,490 | -54 | -2.1% | 14,900 |
| 2024/12/05 | 2,555 | 2,555 | 2,525 | 2,544 | -11 | -0.4% | 10,600 |
| 2024/12/04 | 2,576 | 2,583 | 2,532 | 2,555 | -33 | -1.3% | 20,300 |
| 2024/12/03 | 2,588 | 2,622 | 2,588 | 2,588 | -7 | -0.3% | 10,200 |
| 2024/12/02 | 2,598 | 2,609 | 2,571 | 2,595 | -5 | -0.2% | 11,000 |
| 2024/11/29 | 2,635 | 2,639 | 2,597 | 2,600 | -34 | -1.3% | 8,300 |
| 2024/11/28 | 2,594 | 2,634 | 2,594 | 2,634 | +38 | +1.5% | 7,600 |
| 2024/11/27 | 2,635 | 2,645 | 2,593 | 2,596 | -20 | -0.8% | 10,400 |
| 2024/11/26 | 2,611 | 2,644 | 2,602 | 2,616 | -4 | -0.2% | 7,900 |
| 2024/11/25 | 2,644 | 2,673 | 2,620 | 2,620 | -40 | -1.5% | 11,500 |
| 2024/11/22 | 2,595 | 2,662 | 2,595 | 2,660 | +53 | +2% | 12,000 |
| 2024/11/21 | 2,613 | 2,637 | 2,601 | 2,607 | -6 | -0.2% | 8,000 |
| 2024/11/20 | 2,685 | 2,688 | 2,613 | 2,613 | -85 | -3.2% | 12,200 |
51～
100
件表示中 / 3683件
類似銘柄と比較する
現在ご覧いただいている「扶桑薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 扶桑薬 | 231,400円 | +8.3% | +98.1% | 3.54% | 7.61倍 | 0.53倍 |
|
人工腎臓用透析剤・補液が主軸の製薬中堅、透析剤は国内シェア５割。後発薬や製造受託も展開 |
| ミズホメディ | 148,000円 | +1.2% | -13.9% | 5.74% | 8.73倍 | 1.63倍 |
|
体外検査薬専業、感染症抗体、遺伝子検査機器、試薬開発。新型コロナで急成長、妊娠検査薬も |
| アンジェス | 6,900円 | +110.0% | - | 0.00% | - | 11.01倍 |
|
大阪大医学部、森下竜一教授創業の創薬ベンチャー。遺伝子治療薬を核に核酸医薬など開発多彩 |
| ＣＡＮＢＡＳ | 99,100円 | - | - | 0.00% | - | 6.35倍 |
|
抗がん剤開発に特化した創薬ベンチャー。主力の膵臓がん治療薬候補は自社開発。導出も模索 |
| ステムリム | 30,400円 | - | - | 0.00% | - | 2.80倍 |
|
大阪大学発バイオベンチャー。損傷細胞の活性化物質を動員、再生を促す「再生誘導医薬」を開発 |
市場注目の銘柄
チャート関連のコラム
